FDA Approves Kygevvi (doxecitine and doxribtimine) for the Treatment of Thymidine Kinase 2 Deficiency

Nov 4, 2025 - 11:00
 0  0
ATLANTA, GA, November 3, 2025 – UCB (Euronext Brussels: UCB), a global biopharmaceutical company, today announced that Kygevvi® has been granted approval by the U.S. Food and Drug Administration (FDA) for the treatment of adults and...

What's Your Reaction?

Like Like 0
Dislike Dislike 0
Love Love 0
Funny Funny 0
Angry Angry 0
Sad Sad 0
Wow Wow 0